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ARTICLE
Molecular Diagnostics
WT1 expression in vessels varies with histopathological grade
in tumour-bearing and control tissue from patients with breast
cancer
Richard J. McGregor 1, You-Ying Chau1,2, Timothy J. Kendall2,3, Mara Artibani4, Nicholas Hastie2 and Patrick W. F. Hadoke1
BACKGROUND: The Wilms’ tumour protein (WT1), which inﬂuences tumour development and angiogenesis, is a promising
therapeutic target in breast cancer. We hypothesised that WT1 expression would vary in endothelial cells in distinct sub-
classiﬁcations of breast cancer.
METHODS: WT1 expression and vascular density were quantiﬁed by immunohistochemical analysis of human (n= 57) and murine
breast cancers. Human tumours were sub-classiﬁed by histopathological grade, ER status and HER2 enrichment.
RESULTS: WT1 was identiﬁed in endothelial (and epithelial and smooth muscle) cells in tumours and tumour-free tissues (controls)
from patients and mice with breast cancer. WT1 expression was higher in tumours than in controls, but this was not due to
increased endothelial WT1. Vascular WT1 in cancers decreased as histopathological grade increased. WT1 was higher in ER-positive
versus ER-negative cancers. Strikingly, reduced WT1 expression in controls correlated with an increased Nottingham Prognostic
Index score.
CONCLUSIONS: Expression of WT1 is increased in breast cancers but this is not limited to the vascular compartment. The
association between reduced WT1 in tumour-free tissue and poor prognosis suggests a protective role for WT1 in the healthy
breast.
British Journal of Cancer https://doi.org/10.1038/s41416-018-0317-1
INTRODUCTION
Breast cancer, the most common female malignancy across the
developed. and developing world, is the primary cause of death
among women globally.1 Recently, the Wilms tumour protein
(WT1) has emerged as a potential therapeutic target in this
condition.
WT1, a multi-functional gene fundamental to mammalian
embryological development,2–4 is normally only expressed in
discrete sites in the adult (e.g. in the mesothelium surrounding the
visceral organs, the glomerular podocytes of the kidney, the
sertoli/granulosa cells of the testis/ovary and 1% of bone marrow
cells).5–10 However, substantial evidence, both from solid tumours
and leukaemia, suggests a role for WT1 as an oncogene.11–15
Indeed, such evidence linking WT1 expression with tumour
formation led to the United States National Cancer Institute
ranking WT1 as the cancer antigen with greatest potential as a
target for immunotherapeutic agents.16 Furthermore, since WT1
expression in the vascular endothelium is implicated in the
regulation of angiogenesis,17 increased expression of WT1 in
endothelial cells may contribute to tumour formation, for example
Wagner et al.18 reported WT1 expression in endothelial cells in
95% of 113 solid (lung, ovarian, pancreatic, breast and bladder)
tumours, yet WT1 was not expressed in adjacent healthy tissue.
Crucially, conditional knockout of Wt1 from endothelial and Tie2-
expressing cells markedly reduced both vascularisation and
growth of melanoma (B16) and lung carcinoma (LLC1) in murine
xenografts.19
Considerable evidence has implicated WT1 in the pathogenesis
of breast cancer.20–25 High WT1 mRNA levels in breast tumours
were associated with a lower 5-year disease-free survival rate.26–28
In addition, immunohistochemical analysis associated cytoplasmic
WT1 expression in invading tumour cells with a more biologically
aggressive phenotype (e.g. oestrogen receptor (ER)-negative
tumours > 2 cm in size).22,25 However, the biological basis behind
WT1 expression and poor clinical outcome is not well under-
stood.29 This may be due to inconsistencies in the published data
regarding WT1 mRNA,27,30 the protein expression levels in breast
tumours31,32 or the numerous WT1 isoforms that may have
divergent functional roles5,33,3,20. Indeed, recent work suggests
that the truncated WT1 transcript starting from intron 5 is tumour
speciﬁc.30 Furthermore, few studies have assessed WT1 expression
in histopathological sub-types of breast carcinoma. This may be
important as breast cancer is a profoundly heterogeneous disease
whose correct classiﬁcation is essential for optimal manage-
ment.34 Traditionally, prognosis was determined using a series
of conventional markers, including tumour size, lymph node
involvement, histological grade, oestrogen receptor (ER) status
and epidermal growth factor receptor-2 (HER2) ampliﬁcation
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status.35 More recently, improved analysis of gene expression has
challenged the conventional view that breast cancer is a single
disease.36,37 This may be highly signiﬁcant when contemplating
peptide-based cancer immunotherapies targeting WT1.38
Clearly, a better understanding of the relationship between WT1
and breast cancer is required to inform the development of
immunotherapy for targeting WT-positive tumour cells in this
condition. This investigation addressed the hypothesis that WT1
expression is increased in endothelial cells in human breast
cancers. The speciﬁc aims were to determine whether: (1) WT1
expression is increased in vascular endothelial cells in human
breast cancers; (2) expression of WT1 varies according to Grade
and histopathological stratiﬁcation of tumours; and, (3) whether a
mouse model can be used to assess the role of WT1 in breast
cancer.
MATERIALS AND METHODS
Tissue collection and histopathological analysis of human breast
cancer
All human cancers, and matched healthy control tissue from the
same patients, were obtained via the NRS BioResource and Tissue
Governance Unit funded by the Chief Scientists Ofﬁce (CSO) with
Research Ethics Committee approval (15/ES/0094). Samples were
handled in accordance with the approved guidelines and written
informed consent was obtained from all subjects.
Sections (4 µm) were taken from formalin-ﬁxed, parafﬁn-
embedded tumour blocks from 60 cases of female human
carcinoma of no special type (ductal NST), and matched non-
lesional breast tissue. Consecutive cases were selected where
block keys in anonymised reports allowed identiﬁcation of blocks
from a random, and unknown, period between 2010 and 2013.
Equal numbers of Grade I–Grade III tumours from the right and left
breast were selected. The histopathological grade, ER status,
progesterone receptor status, maximum tumour dimension (mm)
and HER2 enrichment status were obtained from the anonymised
NHS pathology report. Haematoxylin and eosin (H&E) stained
sections from each case were reviewed by a Consultant
Pathologist to conﬁrm appropriate block selection.
Immunoperoxidase staining
Twelve representative tumour samples (x4 Grade I, x4 Grade II, x4
Grade III) and matched controls (n= 12), were stained for WT1
(1:500, C19, #SC- 192, Santa Cruz, USA). All samples were visualised
using the Provis AX-70 Optical Microscope with Axiocam HRc
Camera.
Immunoﬂuorescence
A total of 120 tissue sections (60 tumours and 60 matched
controls) were stained for WT1 (1:500, C19, SC- 192, Santa Cruz,
USA) and CD31 (1:200, Ab28364, Abcam®, UK). For each sample,
ﬁve 200 μm× 200μm regions of interest were randomly selected
and analysed using confocal microscopy to quantify the mean
number of: (a) CD31-expressing cells (endothelial cells); (b) all WT1
expressing cells; (c) cells co-expressing WT1/CD31; (d) vessels; and
(e) WT1+ vessels (deﬁned as a vessel with 2 or more WT1+
endothelial cells). The percentage of WT1+ vessels for each region
of interest within a section was then calculated. These 5
percentages were used to create a mean value for each section.
All analyses were performed blind using an LSM 710 Confocal
microscope (Carl Zeiss, Germany). In addition, the WT1 polyclonal
antibody was combined with its matched blocking peptide (1:500,
SC-192P, Santa Cruz, USA) in a direct competition test on three
patient samples (both lesional and non-lesional control). Finally,
an IgG isotype control (1:100, Ab172730, Abcam®, UK) was used
on human breast tissue sections from lesional (n= 3) and non-
lesional controls (n= 3) to rule out non-speciﬁc cell surface
staining of the WT1 antibody. A detailed analysis of the use of the
C19 WT1 polyclonal antibody in a variety of human cancers has
been described previously.39,40
Preclinical murine model of breast carcinogenesis
The preclinical murine C3(1)/Tag breast cancer line,41 was used
to examine murine breast carcinomas, with standard Friend Virus
B-type (FVB) females acting as controls. All animal experiments
were performed in compliance with the UK Animals (Scientiﬁc
Procedures) Act 1986, under Project Licence PPL 60/3788
approved by the UK Home Ofﬁce. Individual experiments were
approved by the local University of Edinburgh Ethical Review
Committee.
Histopathological analysis of the C3(1)Tag murine model of breast
cancer
Formalin-ﬁxed, parafﬁn-embedded blocks were prepared after
retrieval of the tumour and healthy control breast tissue from the
respective mice. Sections (4 µm) were stained with H&E then
reviewed and veriﬁed by a Veterinary Surgeon and Member of
the European College of Veterinary Pathologists, according to the
consensus report and recommendations into the mammary
pathology of genetically engineered mice, Annapolis 1999.42 Six
tumours (n= 6) and healthy control samples (n= 6) were stained
for Wt1 (1:500, C19, SC-192, Santa Cruz, USA) and CD31 (1:200,
Ab28364, Abcam®, UK) using double immunoﬂuorescence with
tyramide signal ampliﬁcation—utilising a protocol previously
published by our group.43–45 For each sample, ﬁve randomly
selected, 200 μm× 200 μm regions of interest were analysed using
confocal microscopy allowing quantiﬁcation of the mean number
of: (a) CD31-expressing cells; (b) Wt1 expressing cells; (c) cells co-
expressing Wt1/CD31; (d) vessels; and (e) Wt1+ vessels (deﬁned as
a vessel with 2 or more Wt1+ endothelial cells). All analyses were
performed blinded to genotype using an LSM 710 Confocal
microscope (Carl Zeiss, Germany).
A single kidney from each animal was harvested and processed
for Wt1 immunoﬂuorescence as a positive control. In addition, the
WT1 polyclonal antibody was combined with its matched blocking
peptide (1:500, SC-192P, Santa Cruz, USA) in a direct competition
test on three kidney samples as per the manufacturer’s instruc-
tions. Finally, an IgG isotype control (1:100, Ab172730, Abcam®,
UK) was used on kidney sections (n= 3) of FVB control animals to
rule out non-speciﬁc cell surface staining of the WT1 antibody.
Statistics and data analysis
Parametric data are expressed as mean (±standard deviation),
whilst non-parametric data are expressed as median (±interquar-
tile range). In all unpaired analyses Student’s t- and
Mann–Whitney U tests were used for parametric and non-
parametric data, respectively. A one-way analysis of variance
(ANOVA) (plus Tukey’s multiple comparison test) and
Kruskal–Wallis Test with Dunn’s multiple comparisons were used
when comparing the means of two or more unpaired samples
from parametric and non-parametric data samples, respectively.
Correlations were calculated using a two-tailed Pearson’s test.
Statistical signiﬁcance was deﬁned as p < 0.05. All analyses were
performed using Prism 6 for Mac OS X (GraphPad Software Inc.,
USA).
RESULTS
Histopathological analysis of human breast cancer
All 60 human tumour samples and matched controls were
assessed independently by a Consultant Pathologist prior to
analysis. Two tumour cases were excluded as no tumour was
identiﬁed in the selected block. The histopathological grade of the
58 remaining tumour samples documented in the original report
was conﬁrmed. Ten non-lesional control blocks were excluded
from analysis as they contained tumour.
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Identiﬁcation of WT1 in human breast cancer and matched-control
tissues
In a selection of healthy breast tissue samples (n= 12) immuno-
histochemical staining identiﬁed WT1 in some of the endothelial
cells lining the arteries, veins and capillaries (Suppl. Fig. 1).
Moreover, some smooth muscle cells of the arterial wall, and
epithelial cells of the terminal duct lobular unit (TDLU) were also
WT1-positive. In matched breast cancer samples (n= 12; ×4 Grade
I, ×4 Grade II, ×4 Grade III) WT1 staining was observed in tumour
stromal cells, epithelial cells of adjacent benign TDLU, smooth
muscle cells and endothelial cells lining the arteries, veins, and
capillaries of all tumour grades (Suppl. Fig. 1).
More detailed analysis of WT1 expression in breast cancer
samples and matched controls was performed using double
Immunoﬂuorescence. Of the 58 tumours obtained, 1 (and its
matched control) was excluded as the patient had received pre-
operative chemotherapy. Consequently, 57 tumour samples and
49 controls were analysed following double immunoﬂuorescence.
WT1 immunopositivity was identiﬁed in several cell types both
in control breast tissue and in breast cancers (Fig. 1). In control
breast tissue, vessels (arteries, veins and capillaries) could be
identiﬁed with no WT1 staining of the endothelium (Fig. 1a) or
underlying smooth muscle. In contrast, some vessels in these
tissues contained a proportion of WT1-positive endothelial and
smooth muscle cells (Fig. 1b). Breast cancer samples also exhibited
a combination of vessels that did not express WT1, alongside
those containing WT1-positive (endothelial and smooth muscle)
cells (Fig. 1c, d). In addition, epithelial cells lining the TDLU in
health and disease, alongside the tumour stromal cells, were also
positive for WT1 (Fig. 1d).
Quantiﬁcation demonstrated that the total number of WT1-
positive cells was higher in the human breast cancer samples (n=
57) than in matched controls (Fig. 2a). There was no difference
detected in the number of CD31-positive cells (p= 0.053) (Fig. 2b)
or the number of cells that co-expressed WT1/CD31 (Fig. 2c). The
total number of vessels was higher in breast cancers than in
control tissue (Fig. 2d), but no difference was observed in the
number (Fig. 2e) or percentage (Fig. 2f) of WT1-positive vessels.
WT1 expression decreases with histopathological grade of breast
tumour
Of the 56 (from the total of 57) human tumours with grade
available, there were 8 Grade I, 17 Grade II, and 29 Grade III
tumours analysed following immunoﬂuorescent staining. Analysis
of these data demonstrated that WT1 expression decreased with
rising histopathological Grade (Fig. 3). The total numbers of WT1-
positive cells (Fig. 3a), CD31-positive cells (Fig. 3b), and WT1/CD31
dual-positive cells (Fig. 3c) were all higher in Grade I tumours. In
b
c d
a
DAPI
CD31
WT1
DAPI
CD31
WT1
DAPI
CD31
WT1
DAPI
CD31
WT1
50 µm
50 µm
50 µm
50 µm
Fig. 1 WT1 is expressed in human breast cancer and in healthy control tissue. Double immunoﬂuorescence showing a healthy breast tissue
displaying no endothelial WT1 expression in a small capillary. b Healthy breast tissue exhibiting clear expression of WT1 in endothelial (red)
(denoted by broken white arrow) and smooth muscle cells (red) (denoted by white arrow) in the arterial wall. c Breast cancer (Grade II,
ER-positive, HER2-negative) sample displaying WT1+ (red) endothelial cells (CD31+; green) in both the artery and small capillaries; with WT1-
positive smooth muscle cells evident in the arterial media. d Breast cancer (Grade III, ER-positive, HER2-positive) sample exhibiting WT1+ (red)
ducts, arteries and tumour stromal cells. Wt1 (red), CD31 (green), DAPI (blue). Scale bars represent 50 µm
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addition, the numbers of vessels (Fig. 3d), and WT1-positive
vessels (Fig. 3e) were also higher in Grade I breast cancers
compared to Grade II tumours. Interestingly, the percentage of
WT1-positive vessels within the tumours also decreased as tumour
grade increased (Fig. 3f).
WT1 expression in cancer sub-types versus matched-control tissue
Summarising the differences in cellular and vascular expression of
WT1 (Fig. 4a) demonstrated that Grade II and III, but notably not
Grade I, breast cancers exhibited greater expression of WT1-
positive cells than matched-control tissue.
WT1 expression and the Nottingham Prognostic Index (NPI) score
The NPI was calculated using the standard criteria46 for 50 out of
the 57 cancers (not all had their nodal status available). According
to the scoring system, NPI < 3.4 equates to an 85% 5-year survival,
versus NPI > 5.4, which corresponds to a 5-year survival of <50%.47
Stratiﬁcation of cancers by Grade against NPI score demonstrated
a clear increase in NPI with increasing tumour Grade (Fig. 4b).
In the matched-control breast tissue from patients with cancer,
linear regression analysis revealed that the NPI increases as the
number of WT1-positive cells decreases (Fig. 4c). A similar pattern
was observed with cells that co-expressed WT1 and CD31 (Fig. 4d).
This therefore suggests that WT1 expression in health, may be
protective. No difference was detected in the relationship of WT1+
cells, WT1/CD31 co-expression, or the percentage of WT1+ vessels,
with the NPI score, when the cancers were stratiﬁed by Grade (not
shown).
WT1 expression and HER2 status
The association between WT1 and HER2 status was assessed
in 57 cancers. Statistical analysis was undertaken to ascertain
whether the expression pattern of WT1 differed between the
HER2-positive (n= 17) and HER2-negative cancers (n= 40). No
difference was detected between tumour sub-types in the
number of: WT1-positive cells; CD31-positive cells; WT1/CD31-
positive cells; blood vessels; or WT1-positive blood vessels
(Suppl. Fig. 2).
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Fig. 2 WT1 expression is increased in human breast cancers compared with matched-control tissue. The number of WT1+ cells was higher in
tumours than in matched-control tissue (a). No difference was detected in the number of CD31-expressing cells (b) or the number of cells that
co-expressed WT1 and CD31 in the tumours versus matched controls (c). The number of vessels was higher in tumours than in controls (d) but
no difference was detected in the number of WT1 expressing vessels between the tumours and matched-control tissue (e). The percentage of
WT1-positive vessels was not different in tumours and controls (f). a, b Data are mean ± standard deviation where ***p < 0.0005 by unpaired
Student’s t-test, c–e data are median ± interquartile range where **p < 0.01 by Mann–Whitney U test (n= 55)
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WT1 expression in triple-negative breast cancers
There were 15 triple-negative breast cancers in this cohort, with 14
matched controls. The total number of WT1+ cells was increased
in the triple-negative cancers versus tumour-free sections from
matched controls. There was no difference detected in the
total number of CD31+ cells, WT1/CD31 co-localisation, number
of vessels, number of WT1+ vessels, or the percentage of WT1+
vessels (Suppl. Fig. 3).
WT1 expression and oestrogen receptor status
ER status was available for 55 cancers; these cases were
analysed to ascertain whether any difference in WT1 expression
could be detected between ER-positive (n= 32) and ER-negative
tumours (n= 23) (Fig. 5). The number of cells expressing WT1
was not different in ER-positive and ER-negative tumours
(Fig. 5a). However, ER-positive tumours had a higher number
of CD31-positive cells (Fig. 5b), WT1/CD31 co-expressing cells
(Fig. 5c), total blood vessels (Fig. 5d), and WT1-positive blood
vessels (whether expressed as total number (Fig. 5e) or
percentage (Fig. 5f)).
Comparison of WT1 expression in control tissues and breast
cancers stratiﬁed by histopathological status
Supplementary Figure 4A depicts the differences in cellular
and vascular expression of WT1 between a variety of breast
cancer sub-types. Interestingly, all breast cancers, with the
exception of the ER-negative tumours, expressed higher levels
of WT1 versus that of the matched controls, whilst ER-positive
cancers showed the most marked difference from controls,
with higher of WT1-positive, CD31-positive, and WT1/CD31
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Fig. 3 WT1 expression drops as histopathological grade increases in human breast cancers. Grade I tumours expressed more WT1+ cells than
Grade II cancers, but no difference was otherwise detected between tumour Grades (a). Grade I tumours expressed more CD31-positive cells
than with Grade III cancers (b), alongside more cells that co-expressed WT1 and CD31 when compared to both Grade II and Grade III tumours
(c). The number of vessels was higher in Grade I versus Grade III tumours (d) and there were more WT1-positive vessels in Grade I tumours
compared with both Grade II and Grade III tumours (e). The percentage of WT1-positive vessels within the tumours appeared to decrease as
histopathological Grade increased, and this was signiﬁcant when Grade I cancers were compared with Grade III (f). Data are mean ± standard
(where n= 8 Grade I, 17 Grade II, 29 Grade III, deviation); (*p < 0.05, **p < 0.01 and ***p < 0.005 by unpaired Student’s t-test)
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double-positive cells, as well as higher numbers of both total and
WT1-positive vessels (Suppl. Figure 5).
Stratiﬁcation of cancers by histopathological status against NPI
score (Suppl. Figure 4B) demonstrated that the majority of tumour
types had a similar NPI scores (the exception being Grade I
tumours). It is notable, for example, that the NPI scores of ER-
positive tumours (which have relatively high expression of WT1
compared to controls) showed no signiﬁcant different to those
that were ER-negative (which had similar WT1 expression to
control tissues).
WT1 expression and vessel number are increased in the C3(1)Tag
murine model of breast cancer
In healthy murine breast tissue, a proportion of the epithelial cells
of the TDLU expressed Wt1 (Fig. 6a). As in the human tissues,
double immunoﬂuorescence for Wt1 and CD31 of the mammary
tissue of all six FVB controls revealed that a proportion of
endothelial cells of the arteries, veins and capillaries expressed
Wt1 (Fig. 6b). In samples from C3(1)Tag mice, intra-tumoral
stromal cells were Wt1-positive (Fig. 6c), as were some endothelial
cells of the arteries, veins and capillaries (Fig. 6d). TDLU epithelial
cells within the tumours were also noted to be Wt1-positive (not
shown). The numbers of Wt1-positive cells (Fig. 6e), CD31-positive
cells (Fig. 6f), Wt1/CD31 double-positive cells (Fig. 6g), vessels
(Fig. 6h) and Wt1-positive vessels (Fig. 6i) were all higher in
tumours than in controls. In addition, the percentage of vessels
expressing Wt1 was greater in the tumours than control tissue of
FVB mice (Fig. 6j).
DISCUSSION
This investigation addressed the hypothesis that WT1 expression
is increased in vascular endothelial cells in human breast cancers.
Whilst it was demonstrated that global WT1 expression was
elevated in cancer samples, this increase could not be attributed
to increased expression in vascular endothelial cells (despite
increased vascular density in these specimens). However, sub-
analyses based on stratiﬁcation of ER status demonstrated a
higher WT1 expression in ER-positive than ER-negative cancers.
Furthermore, a negative association was identiﬁed between WT1
expression and histopathological Grade. The observation that
reduced cellular expression of WT1 in control tissue was
associated with a worse NPI may suggest a protective role for
WT1 expression in the healthy breast. Ideally, this investigation
would have included control tissue from appropriately matched
cancer free patients, but such samples were not available. Future
studies should consider including disease-free control groups
although acquiring tissue from matched, healthy controls will be
challenging.
The results obtained show clearly that WT1 is expressed in the
endothelial cells, and also in smooth muscle and epithelial cells, of
tumour-free mammary tissue from patients with breast cancer.
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The pattern of expression was notable with only a proportion of
cells expressing WT1 (e.g. a single vessel could contain only one
WT1-positive endothelial cell). This identiﬁcation of WT1 in the
tumour-free sample is perhaps unsurprising, as human reproduc-
tive tissues undergo cyclic remodelling, with angiogenesis a key
part of this physiological process.48 Whilst these results contrast
with previous work reporting no WT1 expression in healthy tissue
from patients with cancer,18 others have detected WT1 in tumour-
free human mammary tissue.22,25 Interestingly, a recent study
demonstrated that normal mammary tissue from a group (n= 5)
of healthy donors expressed higher WT1 mRNA levels than
tumour samples but lacked speciﬁc (exon 1A and intron 5)
isoforms.30 It was also notable that a similar pattern of WT1
expression was seen in control tissue from the C3(1)-Tag
transgenic mouse murine model of breast cancer. These data
suggest that WT1, in several different cellular compartments, has a
role in regeneration of breast tissue. Moreover, the ﬁnding that
loss of WT1 and endothelial WT1 expression in control tissues is
associated with poorer clinical outcomes (i.e. increasing NPI) is
consistent with the homoeostatic role the gene has in other
tissues and organ systems30,47. Future studies should determine
the pattern of WT1 isoform expression in sub-types of human
breast cancer. Unfortunately, molecular analysis was not possible
in the current investigation as tissue extraction did not generate
mRNA of sufﬁcient quality for qPCR.
The demonstration that WT1 expression is increased in
cancerous tissue compared with control sections from the
same patients is consistent with previous reports.19 However,
the mechanism underlying, and the role and signiﬁcance of, this
increase in WT1 remains poorly understood. For example, WT1
expression in invasive ductal carcinoma has been linked to both
improved49 and poor patient outcomes.26 These conﬂicting
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ﬁndings may be due to the fact that analysing cancers en masse is
too blunt an instrument, i.e. subtleties in expression levels
between cancer sub-types may better inform our understandings
of pathogenesis and the appropriateness of targeted therapies.
In our study, we found no correlation between WT1 expression
and NPI score. However, in a sub-group of carcinomas with a
particularly poor prognosis—triple-negative breast cancers—WT1
expression levels were signiﬁcantly higher than in control tissue.
This is consistent with published data that equates high levels of
methylation across the WT1 gene in triple-negative breast cancers
with elevated levels of expression and poor survival.50,51 It should
be reiterated, however, that the higher expression of WT1 in triple-
negative cancers was not due to increased expression in the
vascular endothelium.
The sub-analysis of WT1 expression in endothelial cells versus
histopathological grade clearly shows that as breast carcinomas
become undifferentiated vascular WT1 expression decreases.
Grade III carcinomas are associated with poorer clinical out-
comes,52 suggesting a protective role for endothelial WT1
expression and that perturbations in vascular WT1 expression
within the cancers may be crucial. A limitation of the present study
is the lack of meaningful clinical outcome data. In future
investigations, combining a larger, appropriately powered, patient
cohort, with key clinical outcomes—such as disease-free survival
and all-cause mortality—would strengthen the ability to draw ﬁrm
conclusions.
Previous work from our group demonstrated that WT1 was
higher in ER-positive than ER-negative tumours.30 This contrasts
with the results reported here but it should be noted that
Artibani et al. measured mRNA expression, whereas the immuno-
histological approach used in the current study detects the
WT1 protein. Furthermore, ER positivity falls with increased
grade, so (since WT1 expression dropped as grade increased) a
positive correlation of ER status with WT1 expression is to be
expected. However, ER-positive and ER-negative breast cancers
have been thought to represent distinct disease entities,37,53
and ER-negative breast cancers have poorer clinical outcomes
than ER-positive tumours.34 In this study, ER-positive tumours
show greater vascularisation and WT1 endothelial expression
compared with ER-negative cancers. Whilst no difference was
detected in global WT1 expression between ER-positive and
ER-negative tumours, ER-positive tumours exhibited an expression
proﬁle markedly different from the matched-control tissue, with
increased cellular and vascular WT1 expression. This is mechan-
istically very interesting as WT1 has been shown to interact
with and modulate ER-alpha in vitro.14 These data therefore
have implications for the development of any future therapeutic
agents. For example, the approach for targeting the WT1-peptide
vaccine in ER-negative tumours may need to differ signiﬁcantly
compared to the approach taken with tumours which are
ER-positive.
Many of the molecular features deﬁning the human breast
cancer sub-types have been shown, by DNA microarrays analysis,
to be conserved in murine models.54 For example, 100% of C3(1)-
Tag transgenic mice develop breast cancers and produce a
“mixed” phenotype, with tumours expressing luminal, basal and
mesenchymal genes akin to those seen in basal-like and luminal B
human cancers.55 Our analyses demonstrated marked histological
differences between tumours and control tissues from this model.
Interestingly, the C3(1)/Tag tumours demonstrated an increase in
Wt1+ cells, CD31+ cells, Wt1/CD31 co-localisation, total vessels
and proportion of vessels that are Wt1+, compared to healthy
control tissue. This is consistent with the WT1 upregulation
identiﬁed in the human breast cancer samples versus matched
controls. Moreover, WT1 was expressed in the healthy control
tissue in both species. The observation that the TDLU are WT1-
positive both in the tumours and in healthy controls of both
mouse and human is consistent with the demonstration that
alterations (knock-down or over-expression) in WT1 expression
disrupt the epithelial–mesenchymal balance.30 Such a dual role is
not unexpected given WT1 regulates both epithelial to mesench-
ymal transition (EMT) and mesenchymal to epithelial transition
(MET) during development.2 These studies are particularly
pertinent given this murine model mimics the proliferation
signatures seen in the basal-like human tumours, which are
known to be associated with poorer outcomes in younger
women.53
In conclusion, the data presented in this study demonstrate that
the WT1 gene is expressed in the endothelial (and other) cells of
angiogenic tissues. However, whilst WT1 expression is increased in
breast cancers, this increase cannot be attributed solely to
increased expression in the endothelium. Comparison with control
tissues, and stratiﬁcation of the tumours, suggests that an
improved understanding of the role of WT1 in the healthy breast
and in breast cancer is required to aid the development of
therapies targeting WT1 in this condition. These results emphasise
the need for further mechanistic investigations into the inﬂuence
of WT1 on physiological and pathophysiological angiogenesis. The
similarities seen between the human and murine samples support
the use of the C3(1)/Tag murine tumour model in addressing the
role of WT1 in breast cancer.
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